China Resources Pharmaceutical Group Limited

SHSC:3320 Stock Report

Market Cap: HK$34.1b

China Resources Pharmaceutical Group Past Earnings Performance

Past criteria checks 5/6

China Resources Pharmaceutical Group has been growing earnings at an average annual rate of 4.3%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 8% per year. China Resources Pharmaceutical Group's return on equity is 8.5%, and it has net margins of 1.5%.

Key information

4.3%

Earnings growth rate

4.4%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate8.0%
Return on equity8.5%
Net Margin1.5%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How China Resources Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSC:3320 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24250,4833,77725,5880
31 Mar 24247,5933,81625,4200
31 Dec 23244,7043,85425,2520
30 Sep 23232,5643,57323,9060
30 Jun 23224,6563,38222,9610
31 Mar 23224,5873,51822,7830
31 Dec 22218,1833,50021,9990
30 Sep 22221,4873,72422,2470
30 Jun 22211,7883,71921,1930
31 Mar 22196,2263,28819,6740
31 Dec 21193,0213,07219,3930
30 Sep 21191,4952,86919,6670
30 Jun 21187,5542,62619,7010
31 Mar 21179,5122,72019,0920
31 Dec 20168,7622,77618,1970
30 Sep 20171,8732,68319,1370
30 Jun 20174,9562,57820,1220
31 Mar 20181,0542,79321,2330
31 Dec 19182,6902,93721,8130
30 Sep 19183,4173,67021,9840
30 Jun 19173,9384,18720,9300
31 Mar 19165,6793,73720,0690
31 Dec 18166,6263,49420,3220
30 Sep 18163,7343,46619,5400
30 Jun 18154,8523,30918,0620
31 Mar 18142,2962,95915,7950
31 Dec 17143,6882,90115,0870
30 Sep 17143,2522,75914,2770
30 Jun 17142,2762,60213,3800
31 Mar 17142,0032,57713,3950
31 Dec 16140,3162,52613,2790
30 Sep 16132,2532,16112,5340
30 Jun 16129,3131,88912,2740
31 Mar 16123,7702,10311,7660
31 Dec 15122,7852,38811,6920
31 Dec 14108,5752,1169,9550
31 Dec 1391,3132,0619,2480

Quality Earnings: 3320 has high quality earnings.

Growing Profit Margin: 3320's current net profit margins (1.5%) are higher than last year (1.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 3320's earnings have grown by 4.3% per year over the past 5 years.

Accelerating Growth: 3320's earnings growth over the past year (11.7%) exceeds its 5-year average (4.3% per year).

Earnings vs Industry: 3320 earnings growth over the past year (11.7%) exceeded the Pharmaceuticals industry 9.4%.

Return on Equity

High ROE: 3320's Return on Equity (8.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 12:23
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

China Resources Pharmaceutical Group Limited is covered by 20 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Shun Kei LawCCB International Securities Limited
Zhishun SiuCCB International Securities Limited